Effects of recombinant human endostatin combined with cisplatin chemotherapy on the levels of sPD-L1 and CEA in patients with advanced non-small cell lung cancer
WANG Yuexi
CHEN Xiaomei
YAN Jun
LI Zhiping
Abstract：Objective To study the influence of recombinant human endostatin injection ( Endostar) combined with cisplatin chemotherapy for advanced non small cell lung cancer patients on the levels of programmed death ligand-1 (sPD-L1) and carcinoembryonic antigen ( CEA) in peripheral blood soluble.Methods One hundred patients with advanced non small cell lung cancer from February 2014 to February 2015 in Department of oncology, West China Hospital, Sichuan University were collected.According to the random number table method, they were divided into the control group and the observation group, 50 cases for each group.Paclitaxel and cisplatin were used in the control group, while the observation group was given Endostar injection on the basis of the treatment of control group.Clinical efficacy, sPD-L1, CEA level, quality of life im-provement and adverse reactions were observed and compared between the 2 groups.Results Recent total effective rate of the observation group was 68.0%(34/50), better than that in the control group 18.0%(9/50), and the difference was statisti-cally significant( P <0.05).Compared with those before treatment,the levels of sPD-L1 and CEA were significantly lower in both groups after treatment( P <0.05),and sPD-L1 in the observation group was lower than control group[(1.21 ±0.36)ng/ml vs.(1.50 ±0.40)ng/ml];CEA was lower than control group[(10.24 ±3.02) ng/ml vs.(15.78 ±4.21) ng/ml].The differences were statistically significant( t =3.811,7.561, P <0.05);Total improvement rate of quality of life in the obser-vation group was better than the control group[80.0%(40/50)vs.38.0%(19/50)].The difference was statistically signifi-cant(χ2 =18.231, P <0.05);Total incidence of adverse events in the observation group was lower than the control group [10.0%(5/50) vs.34.0%(17/50)],the difference was statistically significant(χ2 =8.392, P <0.05).Conclusion En-dostar combined with cisplatin chemotherapy in the treatment of patients with advanced non small cell lung cancer has a signifi-cant effect, which is safety and would not increase adverse reactions of chemotherapy.
Keywords：Recombinant human endostatin injectionCisplatinNon-small cell lung cancerSoluble programmed death ligand-1Carcinoembryonic antigen
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 476-478,482 )